

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
13 July 2023 (13.07.2023)



(10) International Publication Number
WO 2023/132789 A3

(51) International Patent Classification:
C07J 63/00 (2006.01) A61K 8/90 (2006.01)
A61K 9/50 (2006.01)

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/SG2023/050003

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(22) International Filing Date:
03 January 2023 (03.01.2023)

(25) Filing Language: English

(26) Publication Language: English

(88) Date of publication of the international search report:
07 September 2023 (07.09.2023)

(30) Priority Data:
10202200186X 07 January 2022 (07.01.2022) SG

(71) Applicants: **AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH** [SG/SG]; 1 Fusionopolis Way, #20-10, Connexis North, Singapore 138632 (SG). **AVIDA HEALTH PTE LTD** [SG/SG]; 2 Venture Drive, #24-01, Vision Exchange, Singapore 608526 (SG).

(72) Inventors: **LIU, Ye**; c/o Institute of Materials Research and Engineering, 2 Fusionopolis Way, #08-03, Innovis, Singapore 138634 (SG). **ZHANG, Zhongxing**; c/o Institute of Materials Research and Engineering, 2 Fusionopolis Way, #08-03, Innovis, Singapore 138634 (SG). **WANG, Guan**; c/o Institute of Materials Research and Engineering, 2 Fusionopolis Way, #08-03, Innovis, Singapore 138634 (SG). **JIANG, Feng Feng**; c/o Avida Health Pte Ltd, 2 Venture Drive, Unit 24-01, Vision Exchange, Singapore 608526 (SG).

(74) Agent: **ALLEN & GLEDHILL LLP**; One Marina Boulevard, #28-00, Singapore 018989 (SG).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: CORE-SHELL CAPSULE COMPRISING MASLINIC ACID

(57) Abstract: The present invention relates to a core-shell capsule comprising maslinic acid embedded in a hydrophobic core comprising a polysorbate with a polyethylene glycol (PEG) moiety, cross-linked with a polyacid or a salt of polyacid to provide a polyethylene glycol-containing hydrophilic shell surrounding the hydrophobic core.

WO 2023/132789 A3